Previous close | 1.8400 |
Open | 2.1300 |
Bid | 1.8200 |
Ask | 1.9000 |
Strike | 160.00 |
Expiry date | 2023-05-19 |
Day's range | 1.7700 - 2.2000 |
Contract range | N/A |
Volume | |
Open interest | 1.4k |
AbbVie has put in a mixed earnings performance, exceeding bottom line estimates in five consecutive quarters but falling short of sales expectations in each instance.
Building a stream of dividends to fatten your wallet every quarter is a lot easier when you're willing to play the long game. AbbVie (NYSE: ABBV) is a passive-income machine, and this is all thanks to its ability to churn out therapies at an industrial scale. Strong earnings growth is likely to continue in the long run -- after a short delay, that is.
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.